INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
TN
Corporate insider

Townsend Richard Nolan

Director, Chief Executive OfficerCIK 0001995218

EDGAR filingsOpen in network
Disclosed transactions11
Buys / sells0 / 6
Max Insider Score39
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A$6,097
2,306 sh
Sep 14, 2026Sep 28, 2026
traded Sep 14, 2026
+14dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Lexeo Therapeutics, Inc.Director, Chief Executive Officer · Nov 20, 2025
2
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A
—
145.5K sh
Sep 24, 2026
Sep 28, 2026
traded Sep 24, 2026
+4d
SEC FORM 4

Evidence

27
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$17K
3,345 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

9
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
67.0K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

39
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$116K
25.9K sh
Jul 1, 2026Jul 1, 2026
traded Jul 1, 2026
+0dSEC FORM 4

Evidence

22
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$17K
3,342 sh
May 18, 2026May 20, 2026
traded May 18, 2026
+2dSEC FORM 4

Evidence

11
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$313K
55.0K sh
Apr 6, 2026Apr 7, 2026
traded Apr 6, 2026
+1dSEC FORM 4

Evidence

25
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$65K
10.2K sh
Feb 18, 2026Feb 20, 2026
traded Feb 18, 2026
+2dSEC FORM 4

Evidence

5
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
646.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
161.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

36
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$10K
1,127 sh
Nov 18, 2025Nov 20, 2025
traded Nov 18, 2025
+2dSEC FORM 4

Evidence